145 related articles for article (PubMed ID: 25738564)
1. Cytotoxic T lymphocyte-associated antigen 4 inhibition increases the antitumor activity of adoptive T-cell therapy when carried out with naïve rather than differentiated T cells.
Ishikawa T; Adachi S; Okayama T; Kokura S; Mizushima K; Doi T; Matsuyama T; Sakamoto N; Katada K; Kamada K; Uchiyama K; Handa O; Takagi T; Naito Y; Itoh Y; Yoshikawa T
Oncol Rep; 2015 May; 33(5):2545-52. PubMed ID: 25738564
[TBL] [Abstract][Full Text] [Related]
2. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
4. CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model.
Son CH; Bae JH; Shin DY; Lee HR; Choi YJ; Jo WS; Ho Jung M; Kang CD; Yang K; Park YS
J Immunother; 2014 Jan; 37(1):1-7. PubMed ID: 24316550
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility.
Pentcheva-Hoang T; Simpson TR; Montalvo-Ortiz W; Allison JP
Cancer Immunol Res; 2014 Oct; 2(10):970-80. PubMed ID: 25038199
[TBL] [Abstract][Full Text] [Related]
6. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
7. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells.
Motoshima T; Komohara Y; Horlad H; Takeuchi A; Maeda Y; Tanoue K; Kawano Y; Harada M; Takeya M; Eto M
Oncol Rep; 2015 Jun; 33(6):2947-53. PubMed ID: 25845968
[TBL] [Abstract][Full Text] [Related]
9. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
10. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes.
Love VA; Grabie N; Duramad P; Stavrakis G; Sharpe A; Lichtman A
Circ Res; 2007 Aug; 101(3):248-57. PubMed ID: 17569889
[TBL] [Abstract][Full Text] [Related]
11. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Selby MJ; Engelhardt JJ; Quigley M; Henning KA; Chen T; Srinivasan M; Korman AJ
Cancer Immunol Res; 2013 Jul; 1(1):32-42. PubMed ID: 24777248
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J
Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
[TBL] [Abstract][Full Text] [Related]
13. PD-1 but not CTLA-4 blockage abrogates the protective effect of regulatory T cells in a pregnancy murine model.
Wafula PO; Teles A; Schumacher A; Pohl K; Yagita H; Volk HD; Zenclussen AC
Am J Reprod Immunol; 2009 Nov; 62(5):283-92. PubMed ID: 19811462
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic-T-lymphocyte-associated antigen 4 blockade abrogates protection by regulatory T cells in a mouse model of microbially induced innate immune-driven colitis.
Watanabe K; Rao VP; Poutahidis T; Rickman BH; Ohtani M; Xu S; Rogers AB; Ge Z; Horwitz BH; Fujioka T; Erdman SE; Fox JG
Infect Immun; 2008 Dec; 76(12):5834-42. PubMed ID: 18824539
[TBL] [Abstract][Full Text] [Related]
15. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
16. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
17. [The role of co-inhibitory signals driven by CTLA-4 in immune system].
Olive D; le Thi S; Xerri L; Hirsch I; Nunès JA
Med Sci (Paris); 2011 Oct; 27(10):842-9. PubMed ID: 22027421
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
[TBL] [Abstract][Full Text] [Related]
19. A DNA vaccine against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) prevents tumor growth.
Lan KH; Liu YC; Shih YS; Tsaid CL; Yen SH; Lan KL
Biochem Biophys Res Commun; 2013 Oct; 440(2):222-8. PubMed ID: 24041689
[TBL] [Abstract][Full Text] [Related]
20. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.
van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM
Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
